# US 2017/0283798 A9 · Ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283798 A9
- Document ID: US20170283798A9
- Status: Published application
- Kind: A9
- Application number: 14/966,110
- Filed: 2015-12-11
- Published: 2017-10-05
- Earliest claimed: 2013-06-14
- Assignees: Deutsches Krebsforschungszentrum
- Applicants: Deutsches Krebsforschungszentrum
- Inventors: Harald ZUR HAUSEN; Ethel-Michel DE VILLIERS; Angel CID-ARREGUI; Victor SARACHAGA DE BENITO
- Web page: https://patentgrep.com/patent/US20170283798A9

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 35/00: Antineoplastic agents
- C12N 15/1131: {against viruses}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/00: Applications; Uses
- C12N 2320/10: in screening processes
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described are TTV miRNAs and probes and primers comprising part of said TTV miRNA polynucleic acid. The use of said compounds for diagnosis of cancer or predisposition of cancer is also described.

## Claims

### Claim 1

A TTV miRNA encoded by a torque teno virus (TTV) polynucleic acid comprising:
(a) a nucleotide sequence depicted in Table 1, 2a or 2b;
(b) a nucleotide sequence having at least 60% identity to the nucleotide sequence of (a) and containing the nucleotide sequence CATCCYY (with Y: C or T); or
(c) a fragment of the nucleotide sequence of (a) or (b) and containing the nucleotide sequence CATCCYY (with Y: C or T);

### Claim 2 (depends on 1)

The TTV miRNA of claim 1, wherein the miRNA is complementary to the polynucleic acid of claim 1 and comprises the nucleotide sequence CAUCCYY (with Y: C or U).

### Claim 3 (depends on 2)

The TTV miRNA of claim 2, wherein the miRNA consists of 19 to 29 nt.

### Claim 4 (depends on 1)

The TTV miRNA of claim 1, wherein the miRNA is a mature TTV molecule derived from a pre-miRNA sequence comprising:
(a) a nucleotide sequence underlined in Table 2a or 2b;
(b) a nucleotide sequence having at least 60% identity to the nucleotide sequence of (a) and containing the nucleotide sequence CATCCYY (with Y: C or T);
(c) a fragment of the nucleotide sequence of (a) or (b) and containing the nucleotide sequence CATCCYY (with Y: C or T);
(d) a nucleotide sequence of Table 1;
(e) a nucleotide sequence having at least 80% identity to the nucleotide sequence of (d) and containing the nucleotide sequence CAUCCYY (with Y: C or U);
(f) a fragment of the nucleotide sequence of (e) or (f) and containing the nucleotide sequence CAUCCYY (with Y: C or U); or
(g) a nucleotide sequence being complementary to a nucleotide sequence of (a) to (f).

### Claim 5

A labelled oligonucleotide probe being capable of acting as a hybridization probe for specific detection of a nucleic acid of a certain TTV isolate and comprising 5 to 50 nucleotides complementary to a nucleotide sequence selected from
(a) a nucleotide sequence in Table 1, Table 2a or 2b;
(b) a nucleotide sequence having at least 60% identity to the nucleotide sequence of (a) and containing the nucleotide sequence CATCCYY (with Y: C or T) or CAUCCYY (with Y: C or U), respectively;
(c) a fragment of the nucleotide sequence of (a) or (b) and containing the nucleotide sequence CATCCYY (with Y: C or T) or CAUCCYY (with Y: C or U), respectively; or
(d) a nucleotide sequence being complementary to a nucleotide sequence of (a), (b) or (c).

### Claim 6

A vector comprising a TTV polynucleic acid selected from:
(a) a nucleotide sequence in Table 1, Table 2a or 2b;
(b) a nucleotide sequence having at least 60% identity to the nucleotide sequence of (a) and containing the nucleotide sequence CATCCYY (with Y: C or T) or CAUCCYY (with Y: C or U), respectively;
(c) a fragment of the nucleotide sequence of (a) or (b) and containing the nucleotide sequence CATCCYY (with Y: C or T) or CAUCCYY (with Y: C or U), respectively; or
(d) a nucleotide sequence being complementary to a nucleotide sequence of (a), (b) or (c).

### Claim 7

A method of diagnosing colon cancer comprising the steps of:
(a) isolating miRNA from a patients sample;
(b) sequencing the miRNA selected in step (a); and
(c) determining if a miRNA selected from the miRNAs is complementary to a sequence shown in Table 2B is present in the sample, whereas the presence of an miRNA complementary to a sequence shown in Table 2B indicates colon cancer.

### Claim 8 (depends on 1)

A method of delivering a lead component for the development of medicament for treatment of colorectal cancer to a patient suffering from colorectal cancer comprising the step of administering an effective amount of an inhibitor of the miRNA of claim 1.

### Claim 9 (depends on 8)

The method of claim 8, wherein the inhibitor is selected from the group consisting of an anti-miR, a miRNA spounge and a tough decoy inhibitor.

### Claim 10 (depends on 1, 8)

The method of claim 8, wherein a pHILP construct is administered which comprising an inhibitor of a miRNA of claim 1 attached thereto.